An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
Phase of Trial: Phase II
Latest Information Update: 24 Mar 2017
At a glance
- Drugs Mavoglurant (Primary)
- Indications Drug-induced dyskinesia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 05 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 15 Apr 2013 Planned End Date changed from 1 Nov 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov.
- 13 Apr 2012 Additional trial locations added as reported by ClinicalTrials.gov.